Nedosiran: First Approval
This article summarizes the milestones in the development of nedosiran leading to this first approval for PH1. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
ConclusionThe travoprost intraocular implant demonstrated robust IOP-lowering and substantially reduced topical IOP-lowering medication burden for up to 36 months following a single administration, while maintaining a favorable safety profile. The travoprost intraocular implant promises to be a meaningful addition to the interventional glaucoma armamentarium by addressing the key shortcomings of topical IOP-lowering medications, including low adherence and topical side effects while controlling IOP for up to 36 months.Trial RegistryClinicalTrials.gov identifier NCT02754596 registered 28 April 2016. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Motixafortide: First Approval
(Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Nedosiran: First Approval
This article summarizes the milestones in the development of nedosiran leading to this first approval for PH1. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
ConclusionThe travoprost intraocular implant demonstrated robust IOP-lowering and substantially reduced topical IOP-lowering medication burden for up to 36 months following a single administration, while maintaining a favorable safety profile. The travoprost intraocular implant promises to be a meaningful addition to the interventional glaucoma armamentarium by addressing the key shortcomings of topical IOP-lowering medications, including low adherence and topical side effects while controlling IOP for up to 36 months.Trial RegistryClinicalTrials.gov identifier NCT02754596 registered 28 April 2016. (Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Motixafortide: First Approval
(Source: Drugs)
Source: Drugs - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Waldenstr öm Macroglobulinemia: Targeted Agents Taking Center Stage
AbstractWith the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for treating patients with Waldenstr öm macroglobulinemia (WM), targeted agents have certainly taken center stage in the therapeutic landscape of WM. This review discusses the biological and clinical data supporting current and up-and-coming targeted agents in WM. Bruton tyrosine kinase inhibitors induce fast, deep, and durable respon ses in patients with WM, comparable to chemoimmunotherapy; however, there is a glaring absence of comparative studies between these regimens. The high response and prog...
Source: Drugs - December 6, 2023 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: Drugs)
Source: Drugs - December 2, 2023 Category: Drugs & Pharmacology Source Type: research
Iruplinalkib: First Approval
This article summarizes the milestones in the development of iruplinalkib leading to this first approval for the treatment of patients with locally advanced or metastaticALK+ NSCLC. (Source: Drugs)
Source: Drugs - November 27, 2023 Category: Drugs & Pharmacology Source Type: research
Correction: Elacestrant: First Approval
(Source: Drugs)
Source: Drugs - November 25, 2023 Category: Drugs & Pharmacology Source Type: research
Motixafortide: First Approval
This article summarizes the milestones in the development of motixafortide leading to this first approval. (Source: Drugs)
Source: Drugs - November 23, 2023 Category: Drugs & Pharmacology Source Type: research
